-DOCSTART- -X- O
From -X- _ O
the -X- _ O
perspective -X- _ O
of -X- _ O
vaccine -X- _ O
development -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
imperative -X- _ O
to -X- _ O
accurately -X- _ O
diagnose -X- _ O
target -X- _ O
infections -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
exclude -X- _ O
subjects -X- _ O
with -X- _ O
prior -X- _ O
exposure -X- _ O
from -X- _ O
evaluations -X- _ O
of -X- _ O
vaccine -X- _ O
effectiveness -X- _ O
, -X- _ O
to -X- _ O
track -X- _ O
incident -X- _ O
infection -X- _ O
during -X- _ O
the -X- _ O
course -X- _ O
of -X- _ O
a -X- _ O
clinical -X- _ O
trial -X- _ O
and -X- _ O
to -X- _ O
differentiate -X- _ O
immune -X- _ O
reactions -X- _ O
due -X- _ O
to -X- _ O
natural -X- _ O
infections -X- _ O
from -X- _ O
responses -X- _ O
that -X- _ O
are -X- _ O
vaccine -X- _ O
related. -X- _ O
When -X- _ O
vaccine -X- _ O
development -X- _ O
is -X- _ O
accelerated -X- _ O
to -X- _ O
a -X- _ O
rapid -X- _ O
pace -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
threats -X- _ O
, -X- _ O
the -X- _ O
challenges -X- _ O
to -X- _ O
develop -X- _ O
such -X- _ O
diagnostic -X- _ O
tools -X- _ O
is -X- _ O
even -X- _ O
greater. -X- _ O
This -X- _ O
was -X- _ O
observed -X- _ O
through -X- _ O
the -X- _ O
recent -X- _ O
expansion -X- _ O
of -X- _ O
Zika -X- _ O
virus -X- _ O
infections -X- _ O
into -X- _ O
the -X- _ O
Western -X- _ O
Hemisphere -X- _ O
in -X- _ O
2014â€“2017. -X- _ O
When -X- _ O
initial -X- _ O
Zika -X- _ B-Intervention
vaccine -X- _ I-Intervention
clinical -X- _ I-Intervention
trials -X- _ I-Intervention
were -X- _ O
being -X- _ O
designed -X- _ O
and -X- _ O
launched -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
the -X- _ O
outbreak -X- _ O
, -X- _ O
there -X- _ O
were -X- _ O
no -X- _ B-Outcome
standardized -X- _ I-Outcome
sets -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
immunological -X- _ I-Outcome
assays -X- _ I-Outcome
, -X- _ O
and -X- _ O
no -X- _ B-Outcome
approved -X- _ I-Outcome
diagnostic -X- _ I-Outcome
tests -X- _ I-Outcome
for -X- _ I-Outcome
Zika -X- _ I-Outcome
virus -X- _ I-Outcome
infection. -X- _ I-Outcome
The -X- _ O
diagnosis -X- _ O
of -X- _ O
Zika -X- _ B-Patient
virus -X- _ I-Patient
infection -X- _ I-Patient
is -X- _ O
still -X- _ O
an -X- _ O
area -X- _ O
of -X- _ O
active -X- _ O
research -X- _ O
and -X- _ O
development -X- _ O
on -X- _ O
many -X- _ O
fronts. -X- _ O
Here -X- _ O
we -X- _ O
review -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
vaccine -X- _ O
clinical -X- _ O
assay -X- _ O
development -X- _ O
and -X- _ O
trial -X- _ O
execution -X- _ O
with -X- _ O
a -X- _ O
special -X- _ O
focus -X- _ O
on -X- _ O
the -X- _ O
state -X- _ O
of -X- _ O
Zika -X- _ O
virus -X- _ O
clinical -X- _ O
assays -X- _ O
and -X- _ O
diagnostics -X- _ O
. -X- _ O

